Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16736892 | 0.86 | LMNA (0.47) | PDE2ALMNAP2RX7AKR1C3AKR1C2 | |
| SCHEMBL18272127 | 0.84 | ALOX15 (0.32) | SMN1; SMN2KDM4EALDH1A1ALOX15 | |
| SCHEMBL16736904 | 0.81 | PDE2A (0.38) | PDE2AAKR1C3AKR1C2SMN1; SMN2KDM4E | |
| SCHEMBL16736919 | 0.81 | LMNA (0.42) | PDE2ALMNAKDM4EALDH1A1ALOX15 | |
| SCHEMBL16736770 | 0.79 | ADRB2 (0.33) | P2RX7ALOX15ALOX12 | |
| SCHEMBL18271887 | 0.74 | ACHE (0.34) | LMNAKDM4EALDH1A1ALOX15ALOX12 | |
| SCHEMBL15256022 | 0.72 | LMNA (0.47) | LMNASMN1; SMN2KDM4EALDH1A1ALOX15 | |
| SCHEMBL18272130 | 0.72 | LMNA (0.38) | LMNASMN1; SMN2KDM4EALDH1A1ALOX15 | |
| SCHEMBL18272145 | 0.71 | ALOX15 (0.36) | PDE2ALMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22723651 | 0.71 | LMNA (0.32) | LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | PDE2A 2920/4885LMNA 2070/4885P2RX7 1564/4885 |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | PDE2A 2920/4885LMNA 2070/4885P2RX7 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.